for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Bayer late-stage rivaroxaban trial meets primary endpoint early

Feb 8 (Reuters) - Bayer AG

* Says Phase III compass study with rivaroxaban in patients with coronary or peripheral artery disease shows overwhelming efficacy and meets primary endpoint early

* Says Bayer, Janssen and Population Health Research Institute (PHRI) will offer rivaroxaban to study participants in an open-label extension trial

* Says a complete data analysis from this study is expected to be presented at an upcoming medical meeting in 2017 Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up